생리활성물질이 증진된 콩발효물의 제조방법 및 이를 통해 제조된 생리활성물질이 증진된 콩발효물
    31.
    发明公开
    생리활성물질이 증진된 콩발효물의 제조방법 및 이를 통해 제조된 생리활성물질이 증진된 콩발효물 有权
    发酵大豆增强生理活性物质及其生理活性物质的制备方法

    公开(公告)号:KR1020160056489A

    公开(公告)日:2016-05-20

    申请号:KR1020140156378

    申请日:2014-11-11

    CPC classification number: A23L11/00 A23C11/10 A23L31/00 A23L33/00 C12R1/225

    Abstract: 본발명은생리활성물질이증진된콩발효물의제조방법및 이를통해제조된생리활성물질이증진된콩발효물에관한것으로써, 콩의배아를발아시키고증자한후, 유산균을도입하여발효함으로써감마-아미노부틸산및 이소플라본등의생리활성물질의함량을증진되고항산화활성을가지는콩 발효물을제조하는방법및 이를통해제조된콩발효물을제공하는데 있다. 본발명에따라제조된생리활성물질이증진된콩발효물은유산균제, 건강식품, 미용식품, 정제나캡슐등과같은기능성식품, 의약품등의소재로서사용할수 있다.

    Abstract translation: 本发明涉及通过该方法制备生理活性物质增强发酵大豆和生理活性物质增强发酵大豆的方法。 本发明提供了一种提高γ-氨基丁酸,异黄酮等生理活性物质含量的发酵大豆的制备方法,具有通过发芽大豆的发芽,蒸发大豆的萌发芽,引入乳酸菌的抗氧化活性 进入大豆的蒸萌发芽,发酵大豆的引入乳酸菌的蒸萌发芽,以及通过制备发酵大豆的方法制备的发酵大豆。 根据本发明制备的生理活性物质增强发酵大豆能够用作乳酸菌浓缩物,保健食品,美容食品,功能性食品如片剂或胶囊剂,药物和医疗用品等的材料。

    〔E〕­N〔5­〔2­〔2­〔2,4­다이히드록시벤질리덴〕히드라지닐〕­2­옥소에틸〕­1,3,4­티아디아졸­2­일〕­4­메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환의 예방 및 치료용 약학적 조성물
    33.
    发明授权
    〔E〕­N〔5­〔2­〔2­〔2,4­다이히드록시벤질리덴〕히드라지닐〕­2­옥소에틸〕­1,3,4­티아디아졸­2­일〕­4­메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환의 예방 및 치료용 약학적 조성물 有权
    包含[E] -N [5- [2- [2- [2,4-二羟基苄基]乙酰胺基] -2-氧代乙基] -1,3,4-噻二唑-2-基] -4-甲氧基苯甲酰胺用于预防的药物组合物 和治疗神经病变疾病

    公开(公告)号:KR101229430B1

    公开(公告)日:2013-02-05

    申请号:KR1020120071710

    申请日:2012-07-02

    Abstract: PURPOSE: A pharmaceutical composition containing (E)-N-(5-(2-(2-(2,4-dihydroxybenzylidene)hydrazinyl)-2-oxoethyl)-1,3,4-thiadiazol-2-yl)-4-methoxybenzamide for preventing and treating neurodegenerative diseases is provided to specifically suppress an S1 pocket of GCP II and to prevent and treat Alzheimer's disease. CONSTITUTION: A pharmaceutical composition for preventing and treating Alzheimer's disease, Parkinson's disease, amylotrophic lateral scelerosis(ALS), or dementia contains (E)-N-(5-(2-(2-(2,4-dihydroxybenzylidene)hydrazinyl)-2-oxoethyl)-1,3,4-thiadiazol-2-yl)-4-methoxybenzamide of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The compound of chemical formula 1 specifically suppresses an S1 pocket of GCP II(glutamate carboxypeptidase II) and strengthens synapses at an early phase.

    Abstract translation: 目的:含(E)-N-(5-(2-(2-(2,4-二羟基亚苄基)肼基)-2-氧代乙基)-1,3,4-噻二唑-2-基)-4 提供了用于预防和治疗神经变性疾病的甲氧基苯甲酰胺,以特异性抑制GCP II的S1口袋并预防和治疗阿尔茨海默氏病。 组成:用于预防和治疗阿尔茨海默氏病,帕金森病,肌营养侧向加速症(ALS)或痴呆的药物组合物含有(E)-N-(5-(2-(2-(2,4-二羟基亚苄基)肼基) - 2-氧代乙基)-1,3,4-噻二唑-2-基)-4-甲氧基苯甲酰胺或其药学上可接受的盐作为活性成分。 化学式1的化合物特异性地抑制GCP II(谷氨酸羧肽酶II)的S1口袋,并在早期阶段增强突触。

    콩 발아배아 추출물을 포함하는 골다공증의 예방 또는 치료용 약학 조성물

    公开(公告)号:KR101898261B1

    公开(公告)日:2018-09-14

    申请号:KR1020180080039

    申请日:2018-07-10

    Abstract: 본발명은콩 발아배아추출물을포함하는골다공증의예방또는치료용약학조성물에관한것으로, 구체적으로콩 발아배아추출물또는이의분획물을포함하는골다공증의예방또는치료용약학조성물, 상기조성물을인간을제외한개체에투여하는단계를포함하는골다공증의예방또는치료방법, 콩발아배아추출물또는이의분획물을포함하는골다공증의예방또는개선용식품조성물, 및사료조성물에관한것이다. 본발명의콩 발아배아추출물은조골세포의증식능및 분화능을향상시키며, 골밀도, 골부피및 골세포의수를증가시키는효과를나타내므로, 골다공증의예방또는치료에유용하게사용될수 있다.

    〔Z〕­N­〔3­〔2,4­디플루오로페닐아미노〕­1­〔4­나이트로페닐〕­3­옥소프로프­1­엔­2­일〕­2­메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환 예방 및 치료용 약학적 조성물
    39.
    发明授权
    〔Z〕­N­〔3­〔2,4­디플루오로페닐아미노〕­1­〔4­나이트로페닐〕­3­옥소프로프­1­엔­2­일〕­2­메톡시벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환 예방 및 치료용 약학적 조성물 有权
    包含(Z)-N-(3-(2,4-二氟苯胺))-1-(4-硝基苯基)-3-氧代壬-1-烯-2-基)-2-甲氧基苯甲酰胺的药物组合物,用于预防和治疗神经递质 疾病

    公开(公告)号:KR101229365B1

    公开(公告)日:2013-02-18

    申请号:KR1020120071703

    申请日:2012-07-02

    Abstract: PURPOSE: A pharmaceutical composition containing (Z)-N-(3-(2,4-difluorophenylamino)-1-(4-nitrophenyl)-3-oxoprop-1-en-2-yl)-2-methoxybenzamide for preventing and treating neurodegenerative diseases is provided to suppress A beta decomposition and to prevent and treat Alzheimer' disease. CONSTITUTION: A pharmaceutical composition for preventing and treating Alzheimer's disease, Parkinson' disease, amylotrophic lateral scelerosis(ALS), or dementia contains (Z)-N-(3-(2,4-difluorophenylamino)-1-(4-nitrophenyl)-3-oxoprop-1-en-2-yl)-2-methoxybenzamide or a pharmaceutically acceptable salt thereof as an active ingredient. The compound of chemical formula 1 specifically suppresses a SI pocket of GCP II(Glutamate Carboxypeptidase II) and strengthens synapse at an early stage. The compound of chemical formula 1 maintains homeostasis of intracellular amyloid beta(A beta).

    Abstract translation: 目的:含有(Z)-N-(3-(2,4-二氟苯基氨基)-1-(4-硝基苯基)-3-氧代-1-烯-2-基)-2-甲氧基苯甲酰胺的药物组合物, 提供治疗神经变性疾病以抑制Aβ分解并预防和治疗阿尔茨海默氏病。 组成:用于预防和治疗阿尔茨海默病,帕金森病,肌营养性侧索加速症(ALS)或痴呆的药物组合物含有(Z)-N-(3-(2,4-二氟苯基氨基)-1-(4-硝基苯基) -3-氧代丙-1-烯-2-基)-2-甲氧基苯甲酰胺或其药学上可接受的盐作为活性成分。 化学式1的化合物专门抑制GCP II(谷氨酸羧肽酶II)的SI口袋,并在早期增强突触。 化学式1的化合物维持细胞内淀粉样蛋白β(Aβ)的体内平衡。

    〔E〕­N­〔2­옥소­1­〔4­옥소­3,4­디하이드로프탈라진­1­ 일〕­2­〔2­〔〔4­옥소­4H­크로멘­3­일〕메틸렌〕하이드라지닐〕에틸〕벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환 예방 및 치료용 약학적 조성물
    40.
    发明授权
    〔E〕­N­〔2­옥소­1­〔4­옥소­3,4­디하이드로프탈라진­1­ 일〕­2­〔2­〔〔4­옥소­4H­크로멘­3­일〕메틸렌〕하이드라지닐〕에틸〕벤즈아마이드를 유효성분으로 함유하는 신경퇴행성 질환 예방 및 치료용 약학적 조성물 有权
    包含(E)-N-(2-氧代-1-(4-氧代-3,4-二氢化哒嗪-1-基)-2-(2 - ((4-氧代-4H-咔啉-3-基) )甲基)乙酰)乙酯)苯甲酰胺用于预防和治疗神经病变疾病

    公开(公告)号:KR101229369B1

    公开(公告)日:2013-02-05

    申请号:KR1020120071706

    申请日:2012-07-02

    CPC classification number: A61K31/502 G01N33/5008

    Abstract: PURPOSE: A pharmaceutical composition containing (E)-N-(2-oxo-1-(4-oxo-3,4-dihydrophthalazin-1-yl)-2-(2-((4-oxo-4H-chromen-3-yl)methylene)hydrazinyl)ethyl)benzamide for preventing and treating neurodegenerative diseases is provided to suppress A beta decomposition and to prevent and treat Alzheimer' disease. CONSTITUTION: A method for screening an agent for preventing and treating Alzheimer's disease, Parkinson's disease, amylotrophic lateral scelerosis(ALS), or dementia comprises: a step of simultaneously and sequentially treating a GCP II(Glutamate Carboxypeptidase II)-expressing cell line with a compound of chemical formula 1 and candidate materials in vitro; a step of measuring the activation level of a S1 or S1' pocket of GCP ii in the cell line; and a step of selecting a candidate material which increases or decreases the activation level compared with a control group.

    Abstract translation: 目的:一种含(E)-N-(2-氧代-1-(4-氧代-3,4-二氢酞嗪-1-基)-2-(2 - ((4-氧代-4H-色烯-4-基) 乙基)苯甲酰胺,用于预防和治疗神经变性疾病,以抑制Aβ分解并预防和治疗阿尔茨海默氏病。 构成:筛选用于预防和治疗阿尔茨海默氏病,帕金森氏病,肌营养性侧索加速症(ALS)或痴呆的药物的方法包括:同时并依次处理表达GCP II(谷氨酸羧肽酶II)的表达细胞系的步骤 化学式1化合物和体外候选物质; 测量细胞系中GCP ii的S1或S1'口袋的活化水平的步骤; 以及与控制组相比选择增加或减少激活水平的候选材料的步骤。

Patent Agency Ranking